Claims
- 1. A method for treating or preventing depression in a mammal, comprising administering to mammal in need thereof:a) a compound of the formula or the pharmaceutically acceptable salt thereof; wherein Z is oxygen, S(O)m wherein m is 0, 1 or 2; or NQ wherein Q is hydrogen, (C1-C6)alkyl or phenyl; X is hydrogen, chloro, fluoro, bromo, iodo, hydroxy, nitro, cyano, (C1-C6)alkyl, trifluoromethyl, (C1-C6)alkoxy, (C1-C6)alkyl S(O)a wherein a is 0, 1 or 2; or phenyl wherein the phenyl group is optionally substituted by hydrogen, halo, hydroxy, nitro, cyano, (C1-C6)alkyl, trifluoromethyl, (C1-C6)alkoxy, or (C1-C6)alkyl S(O)b wherein b is 0, 1 or 2; Y is wherein M is oxygen or sulfur; X is hydrogen, fluoro, chloro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy or (C1-C6)alkyl S(O)c wherein c is 0, 1 or 2; R1 is R6 is selected from the group consisting of hydrogen, (C1-C6)alkyl optionally substituted with (C1-C6)alkoxy or one to three fluorine atoms, or [(C1-C4)alkyl] aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)q—, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chioro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, cyano and (C1-C6)alkylS(O)e, wherein e is 0, 1 or 2; R10 is hydrogen or (C1-C6)alkyl; R2 is hydrogen, (C1-C4)alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, cyano and (C1-C6)alkylS(O)g wherein g is 0, 1 or 2; and R3 is —(CH2)tB, wherein t is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four heteroatoms in the ring, and wherein each of the foregoing phenyl, naphthyl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, COGH and (C1-C6)alkylS(O)h wherein h is 0, 1 or 2; and b) sertraline or a pharmaceutically acceptable salt thereof wherein the amounts of a) and b) are such that the combination is effective in treating or preventing depression.”
- 2. A pharmaceutical composition for treating or preventing depression in a mammal comprising amounts of a) a compound of formula 1 according to claim 1 and b) sertraline or pharmaceutically acceptable salt thereof; wherein the amounts of a) and b) are such that the combination is effective in treating or preventing depression.
Parent Case Info
This application is a divisional application of U.S. patent application Ser. No. 09/291,352, now U.S. Pat. No. 6,277,852 filed Apr. 14, 1999, which claims the benefit of U.S. provisional application Ser. No. 60/081,790, filed Apr. 15, 1998.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4536518 |
Welch et al. |
Aug 1985 |
A |
5130338 |
Bacopoulos et al. |
Jul 1992 |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
0343050 |
Nov 1989 |
EP |
0434561 |
Jun 1991 |
EP |
WO9421619 |
Sep 1994 |
WO |
WO9506044 |
Mar 1995 |
WO |
WO9531988 |
Nov 1995 |
WO |
Non-Patent Literature Citations (4)
Entry |
G. Maura et al., “Serotonin 5-HT1D and 5-HT1A Receptors Respectively Mediate Inhibition of Glutamate Release and Inhibition of Cyclic GMP Production in Rat Cerebellum In Vitro,” J. Neurochemistry, 66(1), 203-209 (1996). |
R. Glennon, “Serotonin Receptors: Clinical Implications,” Neuroscience & Biobehav. Rev., 14, 35-47 (1990.). |
A. Damasio, “450 Alzheimer's Disease and Related Dementias,” in Cecil Textbook of Medicine, 18th ed., pp. 2075-2079 (W. B. Saunders, Philadelphia 1992). |
A. Goldstein, Addiction: from Biology to Drug Policy, pp. 3-5 (W. Freeman & Co. 1994). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/081790 |
Apr 1998 |
US |